HORMONAL CONSEQUENCES OF RENAL METABOLIC ABSENCE

Hormone production
Defective production of erythropoeitin and vitamin D is responsible for two major manifestations of the uremic state: anemia and disordered calcium metabolism.
Erythropoeitin is produced in an undetermined site in the kidney in response to changes in tissue oxygen supply (3) . The levels decrease progressively with renal failure and this decrease is the primary culprit in the anemia developing in uremic patients. Although the liver can produce erythropoeitin, hepatic compensation remains limited, and hence the loss of renal production remains a serious problem (3) .
The kidney is the only site where the pro-active form of vitamin D is converted to the active form of the hormone. This conversion takes place by 1-hydroxylation in the mitochondrial fractions of the proximal tubule (4) . Plasma levels of 1.25-(OHkD 3 are uniformly low or absent in uremia, contributing to the abnormal calcium metabolism (5) . The role played by calcitonin is uncertain. The kidney plays a key role in the degradation of calcitonin and serum calcitonin The International Journal Of Artificial Organs / Vol. 10/ no. 1, 1987/ pp. 20-22 levels are increased in chronic renal failure (6) . In this setting, the effect of failure of the kidney to produce one hormone (vitamin D) may be modified by its inability to metabolize another hormone (calcitonin) affecting the same target system.
An interesting renal hormone system has been championed by Muirhead and his associates (7) . Reno-medullary depressor lipids have been incompletely characterized and exert vasodilator and natriuretic effects. Although they lower blood pressure in some forms of experimental renal hypertension, and although their production may be decreased by renal parenchymal damage, their exact role in the control of blood pressure in uremia remains to be defined.
Hormone metabolism
The loss of functioning renal mass leads to elevation of circulating levels of several hormones, with effects ranging from trivial to major (1) . Fasting hyperinsulinemia and persistently elevated levels after glucose loading are common findings, but simultaneously reduced end-organ responsiveness limits their significance (1) . The decreased degradation of insulin in the diabetic with renal failure decreases insulin requirements (1) . The effects of hyperglucagonemia in uremia are compounded by the coexistence of endorgan hypo and hyperresponsiveness (1) . Somatomedin levels measured by radioimmunoassay are elevated in uremia but the biologically active component is reduced (1) . Clearly then, elevated hormone levels in uremia do not necessarily imply increased hormonal effect. The final result depends on target tissue responsiveness, or increases in levels of a hormone having an opposing effect, or on the circulation of an inactive form of the hormone.
EFFECT OF RENAL METABOLIC ABSEN-CE ON SUBSTRATE HOMEOSTASIS.
Gluconeogenesis
Renal gluconeogenesis plays an important role in carbohydrate homeostasis. Under normal conditions the kidney contributes 20-30% of blood glucose. During. fasting, acidosis or diabetes mellitus, renal gluco-neogenesis provides about 50% of blood glucose (8) . Whether loss of renal mass is associated with a compensatory increase in hepatic gluconeogenesis has not been clearly determined. Furthermore, defective renal gluconeogenesis may contribute to the lability of blood glucose and further predispose the malnourished uremic to spontaneous hypoglycemia (1).
Lactate
At rest lactate is removed mainly by the liver and the kidney. The kidney degrades about 30 percent of lactate. Like the liver, it has the capacity to increase lactate removal under stress from increased lactate loads (9) . Considering that the daily production of lactate is 15 to 30 mEq/kg/day, renal removal can be the equivalent of the total buffer base content of the entire extracellular fluid (10 to 15 mEq/kg). Loss of renal lactate removal with progressive nephron destruction is not usually manifest because hepatic lactate removal remains intact and plays a major compensatory role (1) . If hepatic lactate removal is impaired, however, the uremic patient runs the risk of developing lactic acidosis.
Citrate
The liver and the kidney both metabolize citrate. Plasma citrate levels rise sharply after nephrectomy but return to normal after 24 hours, suggesting extrarenal compensation (10) .
Mevalonate
Mevalonate, an essential intermediate in cholesterologenesis, is produced at the rate-limiting step of the cholesterol synthetic pathway. Two thirds of the produced mevalonate are utilized in cholesterol synthesis and one third is metabolized to fatty acids and C02 by an oxidative pathway. The kidney is the most active site of mevalonate oxidation (11) and nephrectomy reduces mevalonate oxidation and increases cholesterol synthesis from mevalonate in extrarenal tissues (12) . A recent study has shown that mevalonate oxidation is abnormal in almost half of hemodialysis patients (13) . Yet mevalonate oxidation was still present in the majority and was normal in a few, sug-gesting that extrarenal tissues can compensate somewhat for the loss of renal mevalonate oxidation. The possible contribution of abnormal mevalonate oxidation to the hypercholesterolemia and accelerated atherogenesis of uremia (1) needs further investigation.
Myoinositol
Myoinositol is a water-soluble sugar alcohol present in tissues as free myoinositol or as part of phospholipids. Its metabolism involves oxygenation to D-glucorinate, which is further converted to either glucose or completely oxidized to CO2 and water. The initial oxidation step is rate limiting and is catalyzed by the enzyme myoinositol oxygenase present predominantly in the kidney (2) . Nephrectomized animals are incapable of catabolizing myoinositol and there is more than a tenfold increase in myoinositol blood levels in uremia (2) . High levels of myoinositol impair nerve conduction velocity and are toxic to dorsal root ganglia in tissue cultures (2) . The loss of renal myoinositol degradation may thus contribute to the generation of uremic neuropathy.
Clearly then, extrarenal sites can compensate partially for the lost metabolic function by the kidney. The ultimate outcome will depend on such extrarenal alternatives and on the degree of compensation. For many functions, notably hormonal synthesis and catabolism, extrarenal mechanisms are either absent or of limited compensatory capacity. In the orchestration of body homeostasis, extrarenal violas may maintain the flow of harmony, but the loss of renal violins diminishes the richness of the music.
